Technical Report | Published:

Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy

Abstract

Adoptive transfer of T cells modified to express chimeric antigen receptors (CARs) targeting CD19 (CART19s) has demonstrated impressive results in treating B-cell malignancies. Although CART19-induced complications have been gradually recognized, local cytokine-release syndrome (CRS) at particular parts of the body has not been extensively studied. In this paper, we firstly present a successfully treated case of severe dyspnea caused by the rapid enlargement of cervical lymph node following CART19 therapy in a relapsed/refractory DLBCL patient, with emphasis on the recognition, workup, and treatment. This report reminds for a careful evaluation and observation of the pre-existing mass, which could enlarge rapidly again as a result of CRS and be life threatening, in the CART therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A.Flowers CR, 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–59.

  2. 2.

    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA.et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;377:2531–44.

  3. 3.

    Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H.et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Med. 2018;378:439–48.

  4. 4.

    Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö.et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. New Engl J Med. 2017;377:2545–54.

  5. 5.

    Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25–ra25.

  6. 6.

    Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. How I treat: current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.

  7. 7.

    Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol & Oncol. 2018;11:35.

  8. 8.

    Hu Y, Wang J, Pu C, Zhao K, Cui Q, Wei G, et al. Delayed terminal ileal perforation in a relapsed/refractory B-cell lymphoma patient with rapid remission following chimeric antigen receptor T-cell therapy. Cancer Res Treat. 2018;50:1462–66.

  9. 9.

    Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer discov. 2016;6:664–79.

  10. 10.

    Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–48.

  11. 11.

    Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018;23:943–47.

  12. 12.

    Lee D, Gardner R, Porter D. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2016;128:1533.

  13. 13.

    Özdemir E,St, John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ.et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8 + T cells. Blood. 2002;100:3690–7.

Download references

Acknowledgements

This work was supported by grants from 973 Program (2015CB964900), the Natural Science Foundation of China (81470341, 81770201, 81730008), Key Project of Science and Technology Department of Zhejiang Province (2018C03016-2, 2015C03G2150011), and Zhejiang public welfare foundation (GF18H180002).

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to He Huang.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1